IDYA: Multiplikator rega marang pendapatan IDEAYA Biosciences Inc

The success of IDEAYA Biosciences (IDYA) is directly linked to the results of oncology drug trials, while capital remains stable. The price-to-sales multiple on the GURU.Markets base chart contains volatility data, where the indicator holds around 83.90. The brand is recognized as a leader in precision therapy, and drug development operational processes are fully outsourced to external contract research organizations.

IDYA Kapitalisasi marang pendapatan IDEAYA Corp (04.07.2022 - 14.11.2026)

Rincian analitis perusahaan IDEAYA Bio (IDYA)

- rega saham lan konsensus proyeksi valuasi:

Bagan owah-owahan rega ideayabio.com|IDYA - Prakiraan konsensus analis

- informasi kapitalisasi pasar:

Kapitalisasi pasar IDEAYA Bio|IDYA - Nilai Perusahaan

- data kapitalisasi buku:

Nilai Aset Bersih saben Saham IDEAYA Biosciences|IDYA - Aset Bersih Perusahaan|Multiplikator Kapitalisasi Pasar marang Nilai Buku ideayabio.com|IDYA - Total Aset Perusahaan

- statistik kawajiban utang lan likuiditas:

- data bathi lan kelipatan valuasi:

IDYA - Bathi resik|Bathi resik sing dikarepake IDEAYA Biosciences|IDYA - Rasio rega marang bathi|Pangali mangsa ngarep rega marang bathi IDEAYA Biosciences Inc|IDYA - Pangali PEG|Pangali EV/EBITDA IDEAYA Bio|IDYA - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|Bathi saben siji saham sajrone 12 wulan pungkasan IDEAYA Biosciences|IDYA - Bathi resik saben saham sajrone 12 wulan pungkasan|Wutah bathi saben saham ing petungan tahunan sajrone rolas wulan pungkasan ideayabio.com|IDYA - Wutah bathi ing taun lumaku|Prakiraan konsensus wutah bathi saben saham kanggo taun ngarep IDEAYA Biosciences

- indikator pendapatan dodolan lan penghasilan bisnis:

IDYA - Pendapatan lan volume dodolan|Prakiraan pendapatan perusahaan ideayabio.com|IDYA - Multiplikator P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep IDEAYA Bio

Ringkesan analitik perusahaan:ideayabio.com, IDYA

The global humanitarian status of IDEAYA Biosciences (IDYA) developments in targeted cancer therapy minimizes external risks, focusing investor attention on the efficiency of business capitalization. This market capitalization-to-revenue ratio daily compares the company's market value with its actual income, allowing investors to filter out market noise and determine the asset's fair value, thereby preventing an unjustified premium for future successes.

Karo sapa IDEAYA Biosciences saingan

GMAB (genmab.com) - Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S EXEL (Exelixis)|Multiplikator rega marang pendapatan Nuvalent Inc|Kymera Therapeutics Inc - Multiplikator P/S|Rega marang dodolan Enliven Corp|ORIC (ORIC Pharmaceuticals) - Kapitalisasi marang pendapatan|RLAY: Kapitalisasi marang volume dodolan|NRIX (Nurix Therapeutics, Inc.) - Multiplikator P/S|Rega marang dodolan Tyra Biosciences Inc TYRA|Multiplikator P/S VSTM|Monte Rosa Corp - Rasio kapitalisasi marang pendapatan|Cullinan Therapeutics - Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan IMRX|CCCC: Kapitalisasi marang pendapatan|Black Diamond Therapeutics, Inc. - Kapitalisasi marang volume dodolan|RPTX: Multiplikator P/S|PMV Pharmaceuticals, Inc - Rasio kapitalisasi pasar marang pendapatan|KPTI (Karyopharm Therapeutics, Inc.) - Multiplikator P/S|Rega marang dodolan Propanc Biopharma, Inc. PPCB|Rasio rega marang pendapatan Bio Green Med Solution (BGMS)|AADI (aadibio.com) - Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S ALRN (Aileron Therapeutics, Inc.)|Multiplikator P/S Blueprint Medicines Corp. BPMC|GLYC - Rasio rega marang pendapatan|Rasio rega marang dodolan SWTX